DeepMed Research

Ohio State University Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.osu.edu

Clinical Trials

Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

Phase 1

Completed

Conditions: Glioblastoma Multiforme/Anaplastic Astrocytoma

Interventions: Drug: temozolomide
Radiation: Hypofractionated radiation therapy
Radiation: Intensity-modulated radiation therapy

First Posted Date: 2009-02-11

Last Posted Date: 2018-04-18

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT00841555

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: bendamustine
Drug: erlotinib
Drug: Maintenance erlotinib

First Posted Date: 2009-02-03

Last Posted Date: 2018-04-17

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT00834678

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors

Early Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Procedure: PET/CT scan
Drug: 18F-FDG Injection
Procedure: Preoperative 18F-FDG PET/CT Scan
Drug: 18F-FDG for patients with Bladder Cancer
Procedure: Surgical Procedure
Procedure: Specimen PET/CT Scan

First Posted Date: 2009-01-01

Last Posted Date: 2016-04-04

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 65

Registration Number: NCT00816335

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: sorafenib

First Posted Date: 2008-09-18

Last Posted Date: 2019-03-06

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT00754923

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease

Completed

Conditions: Lung Cancer

Interventions: Drug: porfimer sodium
Procedure: bronchoscopy

First Posted Date: 2008-09-18

Last Posted Date: 2018-07-05

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 35

Registration Number: NCT00754910

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Intraocular Melanoma

Interventions: Drug: nab-paclitaxel

First Posted Date: 2008-08-20

Last Posted Date: 2016-02-12

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT00738361

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma
Plasma Cell Neoplasm

Interventions: Drug: lenalidomide
Drug: vorinostat

First Posted Date: 2008-08-07

Last Posted Date: 2020-05-18

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT00729118

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: bevacizumab
Drug: carboplatin
Drug: nab-paclitaxel
Procedure: Surgery
Drug: Adjuvant chemotherapy

First Posted Date: 2008-05-09

Last Posted Date: 2018-07-24

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 33

Registration Number: NCT00675259

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Drug: Vidaza
Drug: Velcade

First Posted Date: 2008-02-28

Last Posted Date: 2017-08-22

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 23

Registration Number: NCT00624936

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

Not Applicable

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Lymphoma
Small Intestine Cancer

Interventions: Biological: Streptococcus pneumoniae
Other: laboratory correlative studies
Other: quality-of-life assessment

First Posted Date: 2007-12-07

Last Posted Date: 2018-03-12

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00569309

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy